A large, nation‑wide study has found that liver‑metabolic disorders markedly raise the risk of developing heart failure in older adults with atrial fibrillation. The research, tracking more than 7,500 people aged 60 and over for roughly nine years, shows that fatty liver disease and alcohol‑related liver injury are not mere bystanders. They appear to amplify the pathway from atrial fibrillation to heart failure, creating a measurable, graded increase in risk.
The findings published in the European Journal of Heart Failure add weight to a growing body of evidence that the liver and the heart communicate in ways clinicians are only beginning to map.
Atrial fibrillation is the most common sustained cardiac rhythm disturbance worldwide. It affects tens of millions of people and is a leading contributor to heart failure, hospital admissions and premature death in older populations. Fatty liver disease — a blanket term for conditions characterised by excess fat in the liver — is similarly common.
It ranges from metabolic dysfunction‑associated steatotic liver disease (MASLD), a form linked to obesity and insulin resistance, through combined metabolic and alcohol‑related forms, to purely alcoholic liver disease. Each subtype carries distinct metabolic and inflammatory signatures, yet all share the potential to produce systemic effects beyond the liver.
Researchers interrogated linked health records to test whether coexisting steatotic liver disease modifies heart failure risk in older adults already living with atrial fibrillation. They compared outcomes for people with and without fatty liver disease and, crucially, analysed risk across three recognised subtypes: MASLD, MASLD with increased alcohol intake, and alcoholic liver disease.
The cohort was followed longitudinally, and incident heart failure events were recorded. Analyses controlled for conventional cardiac risk factors so that the independent contribution of liver‑metabolic status could be isolated.
The headline result was clear. Individuals with any form of steatotic liver disease experienced higher rates of new‑onset heart failure than those without. Risk increased stepwise across the liver disease spectrum. Those with MASLD carried an elevated risk compared with liver‑healthy peers. Risk rose further in people whose fatty liver coexisted with higher alcohol intake. The greatest risk was observed in participants with alcoholic liver disease. The pattern remained robust after statistical adjustment, pointing to an additive effect of metabolic and alcohol‑mediated liver injury on cardiac vulnerability.
The investigators also examined markers that quantify liver fat, alcohol exposure and glycaemic control. They found dose‑response relationships: higher values of the fatty liver index, greater alcohol consumption and elevated fasting glucose were each associated with progressively greater heart failure risk. Put simply, the worse the liver‑metabolic profile, the higher the probability that atrial fibrillation would be followed by heart failure over the follow‑up period.
These findings matter because they widen the lens through which clinicians view atrial fibrillation. Traditionally, risk stratification and management focus on cardiac variables: symptom burden, ventricular rate, anticoagulation to prevent stroke, blood pressure, coronary disease and left ventricular function.
The new evidence suggests liver‑metabolic health is not peripheral. It may be a central determinant of whether atrial fibrillation remains a manageable rhythm disorder or progresses to heart failure. For older adults, who already carry greater baseline cardiovascular risk, the presence of fatty liver disease could tip the balance.
What could explain the liver‑heart connection? Several plausible mechanisms exist. Metabolic dysfunction associated with fatty liver is pro‑inflammatory. Chronic, low‑grade inflammation promotes vascular stress, endothelial dysfunction and adverse cardiac remodelling.
Insulin resistance, a hallmark of MASLD, triggers metabolic derangements that can alter myocardial energy use and promote fibrosis. Alcohol‑related liver disease introduces other toxic pathways, including oxidative stress, direct cardiac toxicity and malnutrition, which together aggravate myocardial dysfunction.
Shared risk factors — obesity, diabetes, hypertension — further blur cause and effect. Still, the graded risk seen across disease subtypes argues that each hepatic pathway contributes additional, measurable hazard.
The study’s implications for clinical practice are tangible. Incorporating liver‑metabolic signals into routine atrial fibrillation reviews could refine risk stratification. Simple, readily available measures — a fatty liver index calculated from routine biochemistry and anthropometry, a structured alcohol history, fasting glucose — may help identify patients at higher risk of heart failure. Those individuals could be prioritised for more intensive surveillance, earlier cardiology input, or targeted preventive strategies.
Prevention is likely to be multi‑faceted. Lifestyle interventions retain centre stage. Weight loss, improved glycaemic control and alcohol moderation all reduce hepatic fat and attenuate systemic metabolic stress.
For individuals with atrial fibrillation, such measures might therefore reduce the downstream risk of heart failure. Pharmacotherapy that targets metabolic drivers of fatty liver disease is an active area of research. Whether specific agents will reduce heart failure risk in this setting remains to be proven.
Nevertheless, the study underlines the potential value of integrated cardiometabolic care — coordinated management that addresses the heart, liver and metabolic milieu together rather than in isolation.
The research team emphasise that screening for fatty liver disease could become a routine element in managing older adults with atrial fibrillation. The approach would be pragmatic. Many patients already undergo blood tests, risk scoring and clinical reviews; adding liver‑related assessments would be low cost and low risk. Focused counselling on weight management, exercise, alcohol intake and diabetes control could then be directed towards those most likely to benefit.
Importantly, the results do not imply that every person with atrial fibrillation and fatty liver will develop heart failure. The study describes population‑level associations and graded risks.
Clinicians should interpret the findings in the context of individual patient profiles. Yet, at the population health level, the message is stark. With ageing populations and rising prevalence of metabolic syndrome and alcohol misuse in many regions, the proportion of people living with both atrial fibrillation and fatty liver disease will increase. Without action, the combined burden could translate into more heart failure, more hospitalisations and greater healthcare costs.
The study’s strengths include its large sample size, long follow‑up and the examination of clinically relevant liver disease subtypes. These design features strengthen confidence that observed associations are not spurious. Limitations remain. Observational studies cannot prove causality. Residual confounding is possible. The measures used to classify liver disease, while practical for large epidemiological studies, are imperfect when compared with biopsy or advanced imaging. Alcohol intake is often under‑reported. Despite these caveats, the consistency of graded risk across multiple liver‑metabolic indicators supports the central conclusion: liver health matters for the heart.
How might guidelines respond? Clinical pathways for atrial fibrillation currently emphasise stroke prevention, rate and rhythm control, and management of comorbidities such as hypertension and diabetes. The integration of liver assessment would be an extension rather than a replacement. Practical steps might include routine calculation of a fatty liver index, systematic enquiry about alcohol intake, and closer monitoring of glycaemic markers. Where significant fatty liver disease is suspected, referral to hepatology or enrolment in multidisciplinary cardiometabolic clinics could be considered.
Policy makers and healthcare planners should note the public health angle. Strategies that reduce obesity, improve metabolic health and curb harmful alcohol use will likely yield cardiovascular dividends that extend beyond the liver. Population‑level interventions, including taxation policies, public education, and support for healthier diets and active lifestyles, remain essential complements to clinical measures.
For researchers, the findings open several avenues. Randomised trials are needed to test whether interventions that improve liver‑metabolic health reduce the incidence of heart failure in people with atrial fibrillation. Mechanistic studies could clarify the biological pathways linking hepatic fat and alcohol‑related injury to myocardial dysfunction. Biomarker discovery may yield novel tools for earlier detection and risk prediction.
Clinicians will find practical guidance in the study’s message: think bigger than the heart. Assess the metabolic ecosystem in which atrial fibrillation exists. Where fatty liver disease is present, act early. Offer lifestyle interventions, tighten glycaemic control, and consider closer cardiovascular surveillance. For patients, this means that discussions about weight, diet, alcohol and diabetes are not ancillary; they are integral to protecting the heart.
The liver‑heart axis is not a metaphor. It is a clinically meaningful connection with implications for how atrial fibrillation is assessed and managed. As evidence mounts, routine cardiology practice may evolve to embrace liver‑metabolic screening as a standard part of risk assessment for older adults with atrial fibrillation.
The likely result — earlier identification of those at heightened risk of heart failure, better targeted prevention, and, ultimately, fewer avoidable cardiac events.
